CAC
BBIO icon

Cowen and Company’s BridgeBio Pharma BBIO Stock Holding History

Cowen and Company’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-72,141
Closed -$2.91M – 677
2023
Q4 		$2.91M Buy
+72,141
New +$2.17M 0.19% 90

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cowen and Company's BBIO Position: Q1 2024 in Review

Cowen and Company sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 72,141 shares — an estimated $2.91M sold.

Cowen and Company first reported a position in BBIO in Q4 2023 and held it in 1 quarter. The position peaked at $2.91M in Q4 2023. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

  • Cowen and Company reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 72,141 BridgeBio Pharma shares in Q1 2024, an estimated $2.91M.
  • Cowen and Company first reported a position in BridgeBio Pharma in Q4 2023 and held it in 1 quarter.
  • Cowen and Company's BridgeBio Pharma position peaked at $2.91M in Q4 2023.
  • 244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.